EA202091961A1 - EXTRACELLULAR VESICULES CONTAINING AGONIST STING - Google Patents

EXTRACELLULAR VESICULES CONTAINING AGONIST STING

Info

Publication number
EA202091961A1
EA202091961A1 EA202091961A EA202091961A EA202091961A1 EA 202091961 A1 EA202091961 A1 EA 202091961A1 EA 202091961 A EA202091961 A EA 202091961A EA 202091961 A EA202091961 A EA 202091961A EA 202091961 A1 EA202091961 A1 EA 202091961A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vesicules
extracellular
immune response
present
sting agonists
Prior art date
Application number
EA202091961A
Other languages
Russian (ru)
Inventor
Су Чул Чжан
Чан Лин Сыа
Нуруддин Д. Льюис
Рэйн А. Харрисон
Рэймонд Дж. Мониз
Срирам Сатьянарайанан
Дуглас Е. Уилльямс
Кириакос Экономидес
Original Assignee
Кодиак Байосайенсес, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кодиак Байосайенсес, Инк. filed Critical Кодиак Байосайенсес, Инк.
Priority claimed from PCT/US2019/023727 external-priority patent/WO2019183578A1/en
Publication of EA202091961A1 publication Critical patent/EA202091961A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены композиции, содержащие ВВ, например экзосому, с инкапсулированными агонистами STING, и способы получения описанных композиций. В настоящем изобретении также предложены способы модулирования иммунного ответа посредством введения терапевтического количества ВВ, например экзосом, с инкапсулированными агонистами STING. Иммунный ответ может представлять собой ответ IFN- или активацию миелоидных дендритных клеток (мДК). В настоящем изобретении также предложены способы модулирования иммунного ответа, не индуцирующего системное воспаление, посредством введения экзосом с инкапсулированными агонистами STING.The present invention provides compositions containing an explosive, eg an exosome, with encapsulated STING agonists, and methods for preparing the disclosed compositions. The present invention also provides methods for modulating the immune response by administering a therapeutic amount of BBs, eg exosomes, with encapsulated STING agonists. The immune response can be an IFN-γ response or activation of myeloid dendritic cells (mDC). The present invention also provides methods for modulating an immune response that does not induce systemic inflammation by administering exosomes with encapsulated STING agonists.

EA202091961A 2019-03-21 2019-03-22 EXTRACELLULAR VESICULES CONTAINING AGONIST STING EA202091961A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962822019P 2019-03-21 2019-03-21
PCT/US2019/023727 WO2019183578A1 (en) 2018-03-23 2019-03-22 Extracellular vesicles comprising sting-agonist

Publications (1)

Publication Number Publication Date
EA202091961A1 true EA202091961A1 (en) 2021-02-20

Family

ID=74855490

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091961A EA202091961A1 (en) 2019-03-21 2019-03-22 EXTRACELLULAR VESICULES CONTAINING AGONIST STING

Country Status (1)

Country Link
EA (1) EA202091961A1 (en)

Similar Documents

Publication Publication Date Title
CO2020013046A2 (en) Extracellular vesicles comprising sting agonist
EA201992131A1 (en) HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION
EA202191975A2 (en) THERAPEUTIC DELIVERY DEVICE
MX2019012819A (en) Bis 2'-5'-rr-(3'f-a)(3'f-a) cyclic dinucleotide compound and uses thereof.
NI201900112A (en) STABLE FORMULATIONS OF ANTIBODIES AGAINST PROGRAMMED DEATH RECEIVER 1 (PD-1) AND METHODS FOR THEIR USE.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
EA202090919A1 (en) Lipid Nanoparticles for the Delivery of Modified RNA Encoding VEGF-A POLYPEPTIDE
PH12020551436A1 (en) Intracellular delivery of biomolecules to modify immune response
MX2020007697A (en) Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses.
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX2019000566A (en) Ev-mediated delivery of binding protein-small molecule conjugates.
TN2018000443A1 (en) Stable liquid pharmaceutical preparation
WO2018115003A3 (en) Novel tnfr agonists and uses thereof
MX2021013657A (en) Antibody drug conjugates.
WO2018081531A3 (en) Methods for human t-cell activation
MX2017016418A (en) Long acting liraglutide compositions.
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2021004331A (en) Stable semaglutide compositions and uses thereof.
MA38975A1 (en) Intrauterine delivery device
EA202091961A1 (en) EXTRACELLULAR VESICULES CONTAINING AGONIST STING
MX2018011149A (en) Extended release conjugates of exenatide analogs.
AR115013A1 (en) EXTRACELLULAR VESICLE INCLUDING STING'S AGONIST
EA201992883A1 (en) ANTIBODIES TO TrkB
WO2021041822A8 (en) Methods of increasing vaccine efficacy
EA202191308A1 (en) DISPOSABLE CASSETTE ASSEMBLY